Mirum Pharmaceuticals delivered a quarter with two opposite stories. The diluted loss was $0.87 per share, 64.2% worse than the -$0.53 consensus and a reversal from a small profit a year earlier, which Earnings Whispers registers as an 1840.0% year-over-year earnings decline. Revenue of $185.72 million beat the $176.46 million consensus by 5.2% and grew 39.6%. Management also raised full-year net product sales guidance for the fourth time this year, to $715 million to $720 million. That is the central tension. The commercial engine keeps outrunning expectations, but Mirum is now spending like a company preparing for several launches at once, and the bottom line shows it.

The miss came from expenses, not demand. Total operating expenses nearly doubled to $245.5 million from $130.4 million. Reported R&D jumped to $107.9 million from $43.0 million, including $42.1 million for brelovitug, and the quarter also carried a $13.5 million IPR&D charge. Stock-based compensation rose to $33.3 million from $18.1 million. The result was a $59.7 million operating loss, versus a $2.6 million operating profit a year ago.

The per-share figures add another wrinkle. Net loss was $40.8 million, or $0.62 per basic share, but $0.87 diluted. That gap suggests the diluted calculation adjusted for convertible-note effects, likely tied to the $16.4 million of other income. Still, the release does not walk through the reconciliation, so investors should be cautious about reading the diluted figure as a clean operating comparison.

On the top line, the trend is steady but uneven. Net product sales moved from $160 million in Q1 to $176 million in Q2 and $186 million in Q3. The $10 million sequential gain was smaller than the prior quarter's $16 million and sits at the low end of the $10 million to $15 million quarterly step-ups management now projects through 2027. The brands diverged:

• LIVMARLI reached $133.4 million, up 45%, but rose only $4 million sequentially.
• U.S. LIVMARLI climbed to $100 million from $92 million, driven mainly by adult PFIC.
• Ex-U.S. LIVMARLI appears to have slipped, consistent with management's comment that Takeda/Japan orders were minimal, with none expected in Q4.
• Bile acid medicines grew 28% to $52.3 million.
• Cash contribution margin held in the high-50s percent range, up from roughly 55% in 2025.

The raised guidance implies Q4 sales of roughly $193 million to $198 million.

The call preserved a credible growth story, and the catalyst calendar is now crowded. ATEBRIOZ won FDA approval for FOP and launched in October, and management expects faster uptake than LIVMARLI saw. Three late-stage readouts all came back positive: AZURE-1 for brelovitug in HDV, EXPAND for LIVMARLI including biliary atresia, and PROGRESS Cohort 2 for pediatric ATEBRIOZ. Those results set up as many as five submissions in the first half of 2027. Brelovitug's BLA still depends on AZURE-4 data due this quarter, and management guided to cash-flow-positive operations in 2027.

Bears have legitimate ammunition, though:

• **PSC filing:** The volixibat PSC NDA, which slipped after the FDA recommended a Phase 3, remains unaligned with the agency. Management is seeking "familiarity, not necessarily complete alignment" and is presenting new IBD-subgroup analyses the FDA has not yet seen. The same liver division will review the EXPAND and PBC filings.
• **Generic exposure:** CHOLBAM is off orphan exclusivity, and the bile acid line is growing large enough to attract generics.
• **Spending:** Cash R&D rose to about $94 million, roughly half of revenue, and is expected to stay elevated for about two more quarters.
• **Cash and leverage:** Cash and investments of $500.5 million are up from $391.4 million at year-end but down from about $561 million in Q2. The release cites $20 million of 2029 notes repurchased, while the call attributes about $62 million of cash outflow to convertible repurchases, a gap the materials do not fully reconcile. Overall convertible debt sits at $731 million, and stockholders' equity has swung to a $54 million deficit after this year's heavy acquired-IPR&D charges.

Investors entered the report skeptical. Earnings Whispers sentiment improved modestly from -0.27 to -0.22 but remains negative. Shares closed at $85.74 the day before the release, down 5.0% from the open after the August report. That leaves the stock 13.0% below its 200-day moving average of $98.50 and 18.1% below its August 19 inter-earnings high of $104.66, though 10.2% above the October 6 low. The market has given back the post-August rally despite repeated guidance increases. The trend readings reflect the same split: sequential growth is positive, while price and AVWAP trends remain negative.

The bottom line is that Mirum's EPS miss reflects a deliberate surge in late-stage investment, not a crack in demand. Revenue, guidance and margins all moved higher, and the pipeline delivered a rare run of clean readouts. But the stock now depends on execution over the next two to three quarters: AZURE-4, the ATEBRIOZ launch, Q4 sales meeting the implied step-up, and a still-unresolved FDA path for PSC. Until spending eases and that regulatory overhang clears, the market appears unwilling to pay for the commercial momentum alone.